Tenaya Therapeutics is a privately-held biopharmaceutical company transforming the treatment of heart disease.
Tenaya Therapeutics is on a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.
Tenaya Therapeutics was founded in 2016 and is based in South San Francisco, California.
Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration.
Tenaya is advancing multiple candidates from three product platforms – Cellular Regeneration, Gene Therapy, and Precision Medicine. Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Tenaya Therapeutics is backed by Casdin Capital, GV, The Column Group and other undisclosed venture and angel investors. The company raised $92M from a "Series B" financing on Oct 3, 2019. The company brings Tenaya's total funding to $142M to date.